Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) Other Gross PP&E Adjustments (2016 - 2025)

Historic Other Gross PP&E Adjustments for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $562.4 million.

  • Amphastar Pharmaceuticals' Other Gross PP&E Adjustments rose 614.08% to $562.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $562.4 million, marking a year-over-year increase of 614.08%. This contributed to the annual value of $517.0 million for FY2024, which is 545.01% up from last year.
  • Amphastar Pharmaceuticals' Other Gross PP&E Adjustments amounted to $562.4 million in Q3 2025, which was up 614.08% from $556.5 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Other Gross PP&E Adjustments peaked at $562.4 million during Q3 2025, and registered a low of $409.8 million during Q3 2021.
  • For the 5-year period, Amphastar Pharmaceuticals' Other Gross PP&E Adjustments averaged around $472.9 million, with its median value being $484.6 million (2023).
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Other Gross PP&E Adjustments crashed by 155.73% in 2021, and later surged by 1583.91% in 2023.
  • Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Other Gross PP&E Adjustments stood at $412.1 million in 2021, then increased by 3.75% to $427.5 million in 2022, then increased by 14.67% to $490.2 million in 2023, then rose by 5.45% to $517.0 million in 2024, then grew by 8.79% to $562.4 million in 2025.
  • Its last three reported values are $562.4 million in Q3 2025, $556.5 million for Q2 2025, and $541.8 million during Q1 2025.